Atara Biotherapeutics’ Stock Soars on Phase 3 Epstein-Barr Virus Data for Lead Asset

New York, February 02, 2024 - PRISM MarketView - Atara Biotherapeutics (NASDAQ: ATRA), a biotech company at the forefront of developing off-the-shelf cell therapies using the natural power of the immune system, experienced a notable 22% increase in its stock value on Thursday, following the publication of Phase 3 ALLELE study data in The Lancet Oncology for its leading candidate, tab-cel. This T-cell therapy has demonstrated significant efficacy in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), marking a pivotal development in the treatment of this condition.

The study’s results showed that out of 43 EBV+ PTLD patients treated with tab-cel, approximately 51% (22 patients) achieved an objective response. This impressive outcome is further underscored by the therapy’s safety profile, as no adverse effects such as cytokine release syndrome, a common concern with CAR-T cell therapies, were reported.

Pascal Touchon, President and CEO of Atara, emphasized the significance of these findings. “The ALLELE study’s results highlight the clinical value of tab-cel, which has now received approval from both EMA and MHRA. It is being made available in Europe through our partner, Pierre Fabre Laboratories, as a first-of-its-kind treatment for a devastating disease with previously limited treatment options,” Touchon stated. He also expressed optimism about the upcoming tab-cel BLA submission to the FDA in the second quarter of 2024, based on the robust clinical data.

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile Epstein-Barr virus (EBV) T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases.

Media Contact
Company Name: Prism MarketView
Email: info@prismmarketview.com
Phone: 646-863-6341
Website: https://prismmarketview.com